Target intelligence / Profile preview

Amino acid and peptide transporter (SLC) (SLC)

Target
SLC
Molecular classification
Transporter, Solute carrier family
01

Overview

Amino acid and peptide transporters represent a broad class of membrane transport proteins, predominantly within the Solute Carrier (SLC) superfamily, responsible for the translocation of amino acids, dipeptides, and tripeptides across biological membranes (Source: UniProt). These transporters, including the SLC15 (peptide) and SLC1, SLC6, and SLC7 (amino acid) families, play vital roles in nutrient absorption in the gut, renal reabsorption, and the regulation of neurotransmitter levels in the central nervous system (Source: PubMed, PMID: 29070610). In oncology, specific transporters like the Large Neutral Amino Acids Transporter 1 (LAT1/SLC7A5) are frequently overexpressed to support the increased protein synthesis and metabolic requirements of tumor cells, serving as both diagnostic biomarkers and therapeutic targets (Source: NIH, National Cancer Institute). Furthermore, these transporters are strategically utilized in pharmacology to improve the pharmacokinetics of drugs; for example, the prodrug valacyclovir is designed to be a substrate for the PEPT1 transporter to enhance its oral bioavailability (Source: PubChem). Genetic mutations in these transporters lead to various metabolic disorders, such as Hartnup disease and lysinuric protein intolerance, emphasizing their critical role in systemic homeostasis (Source: StatPearls).

Other names
Solute carrier transportersAmino acid permeasesPeptide transportersSLC superfamily transportersNutrient transporters
02

Mechanism of action

The primary mechanisms of action include competitive inhibition of substrate transport to starve metabolic pathways (particularly in cancer) and the use of transporters as vehicles for prodrug delivery to increase systemic absorption and cellular entry.

03

Biological functions

Nutrient uptakeNeurotransmitter transportMetabolic regulationProtein synthesisCell signalingpH homeostasis
04

Disease associations

CancerMetabolic disorderNeurological disorderInflammatory bowel diseaseCystinuriaHartnup disease
05

Safety considerations

Nutritional deficiencies due to malabsorptionDisruption of neurotransmitter homeostasisPotential for drug-drug interactions via transporter competitionAlteration of the blood-brain barrier integrity
06

Interacting drugs

Gabapentin

6 more in the full profile.

07

Biomarkers

LAT1 (SLC7A5) expressionPEPT1 (SLC15A1) expressionUrinary amino acid levelsRadiolabeled amino acid uptake

Beyond the preview

Go deeper on Amino acid and peptide transporter (SLC) (SLC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amino acid and peptide transporter (SLC) (SLC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call